Advanced Technology Ventures

Actifio, Inc. specializes in copy data virtualization solutions that streamline data management for enterprises. The company's flagship product, Actifio CDS, supports various applications and storage systems, making it suitable for large-scale deployments within diverse data center environments. Actifio also offers Actifio Sky, a platform designed for distributed enterprises, and Big Data Director, which aids in the protection and recovery of extensive file systems. Additionally, Actifio Resiliency Director provides automated recovery solutions, while OnVault focuses on long-term data retention for business intelligence and compliance. The company enables customers to manage their data more efficiently through its Virtual Data Pipeline™ technology, which decouples data from infrastructure, enhancing business agility and cloud access. With a presence in over 30 countries, Actifio serves numerous global enterprise customers and partners, facilitating a shift towards data-driven decision-making. Founded in 2009 and headquartered in Waltham, Massachusetts, Actifio has expanded its operations internationally, including locations in India, Australia, and Europe.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Founded in 2009 by Marty Kagan and Julien Coulon, two veterans of web hosting and content delivery market, Cedexis optimizes web performance across data centers, delivery networks and clouds for companies that want to reach new global markets. With Cedexis, companies can comparatively assess worldwide cloud performance and availability for informed vendor selection and making cost-and-performance tradeoffs. Cedexis also provides adaptive automation for dynamically optimizing traffic across clouds, data centers and delivery networks to dynamically match the best-performing clouds with local demand. Since revenue conversions and brand experience are directly tied to online performance, media, retail and consumer branded companies rely on Cedexis to ensure 100% availability, fast page loads, downloads and transactions to drive traffic and revenue at lower cost and risk. Cedexis is headquartered in Portland (OR) and Paris (EMEA) with offices in San Francisco (CA), London (UK) and sales representatives in Germany, Japan, Israel and Brazil.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).

Planful, Inc. is a developer of a financial planning and analysis platform designed to assist organizations in various sectors, including education, energy, food, insurance, life sciences, manufacturing, and retail. The Planful platform streamlines business-wide processes such as budgeting, forecasting, consolidations, reporting, and visual analytics, enabling users to enhance efficiency and accuracy in their financial operations. The software eliminates manual processes, facilitates rolling forecasts, and supports strategic planning. With over 1,000 customers, including notable names like the Boston Red Sox and Del Monte, Planful empowers organizations to plan confidently, close faster, and report accurately. Established in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale and Hyderabad, Planful was formerly known as Host Analytics, Inc. and rebranded in December 2019. The company is backed by Vector Capital, a prominent global private equity firm.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Evergage, Inc. is a developer of a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and headquartered in Somerville, Massachusetts, Evergage offers a suite of tools that enable marketers to create individualized experiences for website and mobile app visitors. Its platform combines behavioral analytics and customer data, allowing marketers to understand and respond to users in real time. Key offerings include Evergage Recommend, which provides tailored product and content suggestions; Evergage Promote, which catalogs and promotes assets based on visitor behavior; and Evergage Guardian, which supplies performance insights and recommendations for improving digital interactions. The company serves various industries, including retail, financial services, technology, and travel, and has delivered personalized experiences to over two billion users across more than 150 organizations. Evergage operates as a subsidiary of Salesforce, further enhancing its capabilities in the digital marketing landscape.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Actifio, Inc. specializes in copy data virtualization solutions that streamline data management for enterprises. The company's flagship product, Actifio CDS, supports various applications and storage systems, making it suitable for large-scale deployments within diverse data center environments. Actifio also offers Actifio Sky, a platform designed for distributed enterprises, and Big Data Director, which aids in the protection and recovery of extensive file systems. Additionally, Actifio Resiliency Director provides automated recovery solutions, while OnVault focuses on long-term data retention for business intelligence and compliance. The company enables customers to manage their data more efficiently through its Virtual Data Pipeline™ technology, which decouples data from infrastructure, enhancing business agility and cloud access. With a presence in over 30 countries, Actifio serves numerous global enterprise customers and partners, facilitating a shift towards data-driven decision-making. Founded in 2009 and headquartered in Waltham, Massachusetts, Actifio has expanded its operations internationally, including locations in India, Australia, and Europe.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

Aquion Energy is a manufacturer of innovative energy storage solutions, specializing in sodium ion batteries designed for long-duration stationary energy storage. The company's proprietary Aqueous Hybrid Ion (AHI™) battery technology, developed from research by Carnegie Mellon University Professor Jay Whitacre, addresses the limitations of conventional energy storage systems. Aquion's batteries are safe, reliable, and environmentally friendly, utilizing non-toxic components such as saltwater, and they are free from heavy metals and toxic chemicals. These features make the AHI systems non-flammable and non-explosive, positioning them as a sustainable alternative for clients seeking to decrease reliance on fossil fuels. By optimizing existing grid-tied generation assets, Aquion Energy enhances the flexibility and efficiency of the electrical grid, facilitating the broader adoption of renewable energy technologies.

Aquion Energy is a manufacturer of innovative energy storage solutions, specializing in sodium ion batteries designed for long-duration stationary energy storage. The company's proprietary Aqueous Hybrid Ion (AHI™) battery technology, developed from research by Carnegie Mellon University Professor Jay Whitacre, addresses the limitations of conventional energy storage systems. Aquion's batteries are safe, reliable, and environmentally friendly, utilizing non-toxic components such as saltwater, and they are free from heavy metals and toxic chemicals. These features make the AHI systems non-flammable and non-explosive, positioning them as a sustainable alternative for clients seeking to decrease reliance on fossil fuels. By optimizing existing grid-tied generation assets, Aquion Energy enhances the flexibility and efficiency of the electrical grid, facilitating the broader adoption of renewable energy technologies.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Fuze is a global, cloud-based unified communications platform that empowers productivity and delivers insights across the enterprise by enabling simplified business voice communications, flexible video conferencing, and always-on collaboration. Fuze allows the modern, mobile workforce to seamlessly communicate anytime, anywhere, across any device. Fuze was acquired by 8x8.

Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.

Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary technology, originally conceived at MIT, that enhances traditional zeolite catalysts by introducing novel channels of medium pore size. This innovation allows large hydrocarbon molecules to be processed more efficiently, significantly increasing the yield of transportation fuels such as gasoline and diesel per barrel of crude oil. Rive's catalysts can be integrated seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving product yields and process efficiency, Rive's technology supports the transition to more sustainable energy practices within the petroleum industry.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Planful, Inc. is a developer of a financial planning and analysis platform designed to assist organizations in various sectors, including education, energy, food, insurance, life sciences, manufacturing, and retail. The Planful platform streamlines business-wide processes such as budgeting, forecasting, consolidations, reporting, and visual analytics, enabling users to enhance efficiency and accuracy in their financial operations. The software eliminates manual processes, facilitates rolling forecasts, and supports strategic planning. With over 1,000 customers, including notable names like the Boston Red Sox and Del Monte, Planful empowers organizations to plan confidently, close faster, and report accurately. Established in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale and Hyderabad, Planful was formerly known as Host Analytics, Inc. and rebranded in December 2019. The company is backed by Vector Capital, a prominent global private equity firm.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Planful, Inc. is a developer of a financial planning and analysis platform designed to assist organizations in various sectors, including education, energy, food, insurance, life sciences, manufacturing, and retail. The Planful platform streamlines business-wide processes such as budgeting, forecasting, consolidations, reporting, and visual analytics, enabling users to enhance efficiency and accuracy in their financial operations. The software eliminates manual processes, facilitates rolling forecasts, and supports strategic planning. With over 1,000 customers, including notable names like the Boston Red Sox and Del Monte, Planful empowers organizations to plan confidently, close faster, and report accurately. Established in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale and Hyderabad, Planful was formerly known as Host Analytics, Inc. and rebranded in December 2019. The company is backed by Vector Capital, a prominent global private equity firm.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Modria, Inc. is a developer of a cloud-based online dispute resolution platform that automates the resolution of customer disputes related to eCommerce. Founded in 2011 and headquartered in San Jose, California, with an additional office in Chennai, India, the company serves a diverse clientele, including tangible goods and service marketplaces, payment networks, medium and large online merchants, government agencies, and classified sites. The platform seamlessly integrates with both the back-end architecture and front-end user experience of eCommerce sites, enabling businesses to efficiently resolve customer issues without the need for human intervention. As of May 30, 2017, Modria operates as a subsidiary of Tyler Technologies, Inc.

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).

Fuze is a global, cloud-based unified communications platform that empowers productivity and delivers insights across the enterprise by enabling simplified business voice communications, flexible video conferencing, and always-on collaboration. Fuze allows the modern, mobile workforce to seamlessly communicate anytime, anywhere, across any device. Fuze was acquired by 8x8.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

QuickPay was founded in 2010 with a vision to leverage trends in mobile technology to remove the pain and hassle of finding, accessing, and paying for parking and transportation. Their revolutionary QP QuickPay mobile parking platform offers users one mobile parking application that works across all parking environments — drivers can even raise parking gates using their mobile phones — and gives parking owners and operators an efficient way to enable mobile parking across all their assets with a single integrated solution. Today drivers can use QP QuickPay and a mobile phone to find and pay for parking at hundreds of locations across the U.S., with new locations being added continually.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Evergage, Inc. is a developer of a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and headquartered in Somerville, Massachusetts, Evergage offers a suite of tools that enable marketers to create individualized experiences for website and mobile app visitors. Its platform combines behavioral analytics and customer data, allowing marketers to understand and respond to users in real time. Key offerings include Evergage Recommend, which provides tailored product and content suggestions; Evergage Promote, which catalogs and promotes assets based on visitor behavior; and Evergage Guardian, which supplies performance insights and recommendations for improving digital interactions. The company serves various industries, including retail, financial services, technology, and travel, and has delivered personalized experiences to over two billion users across more than 150 organizations. Evergage operates as a subsidiary of Salesforce, further enhancing its capabilities in the digital marketing landscape.

EndPlay is a leading provider of SaaS Content Management, Engagement and Monetization solutions delivered in the cloud. Powered by its unique 'Intelligent Rendering' technology, EndPlay's end-to-end Platform provides a streamlined user experience that empowers clients to seamlessly produce, manage and instantly deliver content optimized for virtually any device. The company's extensible architecture and integrated partners ensure EndPlay clients can expand, engage, monetize and leverage their content management solution against the complexities facing all brands in the era of Big Data and Quantum Content. Enterprise clients in media, entertainment, consumer packaged goods (CPG) and education verticals have turned to EndPlay's experienced Client Services team to support collaboration, implementation and optimization of their EndPlay solutions. EndPlay’s commitment to innovation and customer-centric approach enables clients to stay ahead of their competition, increase audience engagement, and future-proof their digital business investment. All EndPlay associates are certified to meet the company's rigorous standards of customer service. Partners and clients can also leverage EndPlay's certification process to increase platform productivity and achieve business goals. EndPlay is headquartered in Los Angeles, California with regional offices in Florida and New Jersey, and currently expanding to Europe and Asia. For more information, visit www.endplay.com.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Actifio, Inc. specializes in copy data virtualization solutions that streamline data management for enterprises. The company's flagship product, Actifio CDS, supports various applications and storage systems, making it suitable for large-scale deployments within diverse data center environments. Actifio also offers Actifio Sky, a platform designed for distributed enterprises, and Big Data Director, which aids in the protection and recovery of extensive file systems. Additionally, Actifio Resiliency Director provides automated recovery solutions, while OnVault focuses on long-term data retention for business intelligence and compliance. The company enables customers to manage their data more efficiently through its Virtual Data Pipeline™ technology, which decouples data from infrastructure, enhancing business agility and cloud access. With a presence in over 30 countries, Actifio serves numerous global enterprise customers and partners, facilitating a shift towards data-driven decision-making. Founded in 2009 and headquartered in Waltham, Massachusetts, Actifio has expanded its operations internationally, including locations in India, Australia, and Europe.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Aquion Energy is a manufacturer of innovative energy storage solutions, specializing in sodium ion batteries designed for long-duration stationary energy storage. The company's proprietary Aqueous Hybrid Ion (AHI™) battery technology, developed from research by Carnegie Mellon University Professor Jay Whitacre, addresses the limitations of conventional energy storage systems. Aquion's batteries are safe, reliable, and environmentally friendly, utilizing non-toxic components such as saltwater, and they are free from heavy metals and toxic chemicals. These features make the AHI systems non-flammable and non-explosive, positioning them as a sustainable alternative for clients seeking to decrease reliance on fossil fuels. By optimizing existing grid-tied generation assets, Aquion Energy enhances the flexibility and efficiency of the electrical grid, facilitating the broader adoption of renewable energy technologies.

Founded in 2009 by Marty Kagan and Julien Coulon, two veterans of web hosting and content delivery market, Cedexis optimizes web performance across data centers, delivery networks and clouds for companies that want to reach new global markets. With Cedexis, companies can comparatively assess worldwide cloud performance and availability for informed vendor selection and making cost-and-performance tradeoffs. Cedexis also provides adaptive automation for dynamically optimizing traffic across clouds, data centers and delivery networks to dynamically match the best-performing clouds with local demand. Since revenue conversions and brand experience are directly tied to online performance, media, retail and consumer branded companies rely on Cedexis to ensure 100% availability, fast page loads, downloads and transactions to drive traffic and revenue at lower cost and risk. Cedexis is headquartered in Portland (OR) and Paris (EMEA) with offices in San Francisco (CA), London (UK) and sales representatives in Germany, Japan, Israel and Brazil.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments to enhance the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K), which is approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma after previous therapies. Additionally, Verastem is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, currently being studied in combination with immunotherapies for various cancers, including pancreatic and non-small cell lung cancer. The company focuses on targeting critical signaling pathways in cancer to inhibit tumor growth and promote cell death. Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited, and is headquartered in Needham, Massachusetts.

Evergage, Inc. is a developer of a cloud-based real-time personalization platform aimed at enhancing customer engagement for digital marketers. Founded in 2010 and headquartered in Somerville, Massachusetts, Evergage offers a suite of tools that enable marketers to create individualized experiences for website and mobile app visitors. Its platform combines behavioral analytics and customer data, allowing marketers to understand and respond to users in real time. Key offerings include Evergage Recommend, which provides tailored product and content suggestions; Evergage Promote, which catalogs and promotes assets based on visitor behavior; and Evergage Guardian, which supplies performance insights and recommendations for improving digital interactions. The company serves various industries, including retail, financial services, technology, and travel, and has delivered personalized experiences to over two billion users across more than 150 organizations. Evergage operates as a subsidiary of Salesforce, further enhancing its capabilities in the digital marketing landscape.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

[x+1] is the only marketing technology company recognized as a leader in both the Forrester DMP and DSP Wave Reports. [x+1] Origin Platform is a programmatic marketing hub that empowers the world's best brands to engage audiences in progressively relevant conversations across a full spectrum of paid and owned digital channels. [x+1] Origin Data Management Platform (DMP), powered by the Predictive Optimization Engine (POE™) and a wholly-integrated DSP, blends first and third-party data with predictive decisioning to engage audiences across online display, mobile web, apps, email, site, and other digital channels. This is why the world’s best brands including seven of the top financial services advertisers rely on [x+1] for their programmatic marketing. The company is headquartered in New York City with offices in Connecticut, Illinois, Michigan and California. For more information visit www.xplusone.com

Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary technology, originally conceived at MIT, that enhances traditional zeolite catalysts by introducing novel channels of medium pore size. This innovation allows large hydrocarbon molecules to be processed more efficiently, significantly increasing the yield of transportation fuels such as gasoline and diesel per barrel of crude oil. Rive's catalysts can be integrated seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving product yields and process efficiency, Rive's technology supports the transition to more sustainable energy practices within the petroleum industry.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Actifio, Inc. specializes in copy data virtualization solutions that streamline data management for enterprises. The company's flagship product, Actifio CDS, supports various applications and storage systems, making it suitable for large-scale deployments within diverse data center environments. Actifio also offers Actifio Sky, a platform designed for distributed enterprises, and Big Data Director, which aids in the protection and recovery of extensive file systems. Additionally, Actifio Resiliency Director provides automated recovery solutions, while OnVault focuses on long-term data retention for business intelligence and compliance. The company enables customers to manage their data more efficiently through its Virtual Data Pipeline™ technology, which decouples data from infrastructure, enhancing business agility and cloud access. With a presence in over 30 countries, Actifio serves numerous global enterprise customers and partners, facilitating a shift towards data-driven decision-making. Founded in 2009 and headquartered in Waltham, Massachusetts, Actifio has expanded its operations internationally, including locations in India, Australia, and Europe.

Qumu Corporation specializes in providing comprehensive solutions for creating, managing, securing, distributing, and measuring live and on-demand video content specifically tailored for enterprises. The company's platform enhances employee engagement and modernizes workplace communication by enabling efficient knowledge sharing. Qumu's offerings include software licenses, server appliances, software-enabled devices, and cloud-hosted services, complemented by maintenance and support as well as professional services. The company serves a diverse clientele across various sectors, including banking, finance, insurance, manufacturing, telecom, technology, and healthcare, as well as government entities. Its primary market is in North America, with additional reach in Europe and Asia. Headquartered in Minneapolis, Minnesota, Qumu was established in 1978 and rebranded from Rimage Corporation in 2013.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer's disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.

Calxeda provides revolutionary efficiency to the data center. Leveraging ultra-low power technology from ARM, servers built on Calxeda’s silicon and software platform consume a fraction of the power and space of today’s best-in-class servers, enabling data centers to realize significant reduction in capital and operating expenses. The Calxeda platform scales efficiently to thousands of server nodes, with unique network and storage acceleration, and is enhanced with management technology to deliver true “energy-proportional” computing. The result is a stunning breakthrough in performance efficiency, density, and scalability.

Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Planful, Inc. is a developer of a financial planning and analysis platform designed to assist organizations in various sectors, including education, energy, food, insurance, life sciences, manufacturing, and retail. The Planful platform streamlines business-wide processes such as budgeting, forecasting, consolidations, reporting, and visual analytics, enabling users to enhance efficiency and accuracy in their financial operations. The software eliminates manual processes, facilitates rolling forecasts, and supports strategic planning. With over 1,000 customers, including notable names like the Boston Red Sox and Del Monte, Planful empowers organizations to plan confidently, close faster, and report accurately. Established in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale and Hyderabad, Planful was formerly known as Host Analytics, Inc. and rebranded in December 2019. The company is backed by Vector Capital, a prominent global private equity firm.

Altura Medical, Inc. is a medical device company based in Menlo Park, California, focused on developing advanced endograft technology for the treatment of abdominal aortic aneurysms (AAA) and related conditions. The company's primary product is the Agili-D AAA System, an innovative endovascular aneurysm repair technology designed to improve patient outcomes. Founded in 2008, Altura Medical has garnered support from a notable group of venture capital investors and is led by a seasoned management team. The company operates as a subsidiary of Lombard Medical, Inc. as of July 2015.

Zeltiq Aesthetics, founded in 2005 and headquartered in Pleasanton, California, is a medical technology company focused on developing non-invasive solutions for the reduction of unwanted fat tissue. The company's flagship product, the CoolSculpting system, employs a patented technology known as Cryolipolysis, which utilizes controlled cooling to selectively target and eliminate fat cells while preserving surrounding skin and tissue. This FDA-cleared treatment provides a non-surgical option for individuals seeking to reduce stubborn fat bulges. Zeltiq distributes its products through a direct sales force and a network of distributors, catering primarily to dermatologists, plastic surgeons, and aesthetic specialists across North America, Europe, the Asia-Pacific, and Latin America. The company was previously known as Juniper Medical, Inc. before rebranding in 2007. As of 2017, Zeltiq operates as a subsidiary of Allergan plc.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Silicor Materials, Inc. specializes in the production of solar silicon for photovoltaic cell and module manufacturers globally. Established in 2006 and headquartered in San Jose, California, the company operates manufacturing facilities in Vaughan, Canada, and Mississippi, along with a research and development center in Berlin, Germany. Silicor Materials offers high-quality, low-cost solar silicon, which serves as an alternative to more expensive electronic-grade silicon, thereby enabling photovoltaic module manufacturers to lower their production costs while adhering to demanding performance standards. In addition to solar silicon, the company produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride, which are utilized in municipal and industrial water treatment applications.

Planful, Inc. is a developer of a financial planning and analysis platform designed to assist organizations in various sectors, including education, energy, food, insurance, life sciences, manufacturing, and retail. The Planful platform streamlines business-wide processes such as budgeting, forecasting, consolidations, reporting, and visual analytics, enabling users to enhance efficiency and accuracy in their financial operations. The software eliminates manual processes, facilitates rolling forecasts, and supports strategic planning. With over 1,000 customers, including notable names like the Boston Red Sox and Del Monte, Planful empowers organizations to plan confidently, close faster, and report accurately. Established in 2007 and headquartered in Redwood City, California, with additional offices in Scottsdale and Hyderabad, Planful was formerly known as Host Analytics, Inc. and rebranded in December 2019. The company is backed by Vector Capital, a prominent global private equity firm.

Nuventix, based in Austin, Texas, specializes in active thermal management solutions, particularly through its patented SynJet module. This innovative synthetic jet cooling technology generates turbulent pulses of air using an electromagnetic actuator to effectively manage heat removal. Initially successful in computer cooling applications, Nuventix has made significant strides in the LED cooling market, advancing it by two years ahead of industry analysts' estimates. This progress not only enhances cooling efficiency but also supports the development of general illumination designs that leverage the benefits of LED technology.

Ardian is an independent private investment company founded in 1996 and headquartered in Paris, France. The firm specializes in private equity investments, focusing on a diverse range of sectors including food and beverage, agribusiness, healthcare, life sciences, pharmaceuticals, technology, and logistics. Ardian targets companies primarily in Europe and North America, seeking to create value through strategic investments and partnerships. The company is committed to ensuring that the benefits of its investments are distributed widely among stakeholders.

GI Dynamics, Inc., a medical device company, develops therapies for the treatment of type 2 diabetes and related metabolic diseases in the United States. Its products also include EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The company was founded in 2003 and is based in Lexington, Massachusetts.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

CombineNet, Inc. is an advanced sourcing technology company that has been delivering value to mid-sized and global organizations for over a decade. The company specializes in sourcing and optimization technologies tailored for supply-chain-based organizations across various industries. Its flagship product, CombineNet ASAP (Advanced Sourcing Application Platform), is a web-based software-as-a-service solution that enables sourcing teams to efficiently create, launch, and manage sourcing events of any complexity. This platform focuses on strategically sourcing complex spend categories and enhancing sourcing-award decisions through optimization, thereby streamlining the supplier and spend decision-making process.

Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.

Silicor Materials, Inc. specializes in the production of solar silicon for photovoltaic cell and module manufacturers globally. Established in 2006 and headquartered in San Jose, California, the company operates manufacturing facilities in Vaughan, Canada, and Mississippi, along with a research and development center in Berlin, Germany. Silicor Materials offers high-quality, low-cost solar silicon, which serves as an alternative to more expensive electronic-grade silicon, thereby enabling photovoltaic module manufacturers to lower their production costs while adhering to demanding performance standards. In addition to solar silicon, the company produces aluminum by-products, including aluminum-silicon master alloys and polyaluminum chloride, which are utilized in municipal and industrial water treatment applications.

Anagran specializes in flow-based traffic management products designed to mitigate the adverse effects of network congestion, thereby facilitating the seamless scaling of video, voice, data, and wireless traffic across converged IP networks. The company's solutions protect essential network traffic by managing end-to-end flows based on their behavior, ensuring optimal quality and performance levels without relying on invasive deep packet inspection techniques. This approach allows service providers and enterprises to consistently achieve high-performance standards while significantly lowering both capital expenditures and ongoing network costs. Founded by Dr. Larry Roberts, a recognized pioneer of the Internet, Anagran is committed to enhancing network efficiency and reliability.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative drug delivery solutions for patients with Type 2 diabetes. The company's primary product was the V-Go, a disposable insulin delivery device designed for continuous basal and on-demand bolus dosing, aimed at simplifying insulin management for users. Valeritas also worked on the V-Go Prefill, intended to streamline the device-filling process, and the V-Go SIM, which provided real-time tracking of insulin dosing. Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas sold its products through third-party wholesalers and medical supply distributors. However, the company filed for Chapter 11 bankruptcy on June 30, 2020, ceasing operations.

Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.

ChannelAdvisor is a provider of cloud-based multichannel commerce solutions aimed at enhancing the e-commerce operations of brands and retailers. The company's platform facilitates the management of various sales channels, enabling users to streamline processes such as inventory availability and pricing optimization. By offering data analytics capabilities, ChannelAdvisor empowers its clients to improve their online performance and competitiveness. The company is dedicated to helping businesses expand their reach, connect with consumers throughout the buying cycle, and ultimately drive sales growth from a centralized platform.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

AltaRock Energy is a renewable energy development company that specializes in Engineered Geothermal Systems (EGS). Based in Sausalito, California, with a technology development office in Seattle, Washington, the company is dedicated to the research and commercialization of geothermal energy solutions. AltaRock has developed a portfolio of patents related to EGS technology and holds exclusive licenses for relevant intellectual property. The company's innovative approach aims to provide clean, affordable, and renewable energy by enhancing existing geothermal power sites and reducing risks associated with dry holes. This technology not only expands the capacity of current geothermal resources but also increases profitability for the energy industry, making renewable energy more accessible. Key leaders in the company include Chief Executive Officer Don O'Shei and President/Chief Technology Officer Susan Petty, who is also a founder of AltaRock.

Qumu Corporation specializes in providing comprehensive solutions for creating, managing, securing, distributing, and measuring live and on-demand video content specifically tailored for enterprises. The company's platform enhances employee engagement and modernizes workplace communication by enabling efficient knowledge sharing. Qumu's offerings include software licenses, server appliances, software-enabled devices, and cloud-hosted services, complemented by maintenance and support as well as professional services. The company serves a diverse clientele across various sectors, including banking, finance, insurance, manufacturing, telecom, technology, and healthcare, as well as government entities. Its primary market is in North America, with additional reach in Europe and Asia. Headquartered in Minneapolis, Minnesota, Qumu was established in 1978 and rebranded from Rimage Corporation in 2013.

Rive Technology is a clean energy company focused on advancing catalyst technology for petroleum refining. The company has developed a proprietary technology, originally conceived at MIT, that enhances traditional zeolite catalysts by introducing novel channels of medium pore size. This innovation allows large hydrocarbon molecules to be processed more efficiently, significantly increasing the yield of transportation fuels such as gasoline and diesel per barrel of crude oil. Rive's catalysts can be integrated seamlessly into existing refinery operations, enabling refiners to boost throughput and profitability with minimal capital investment. By improving product yields and process efficiency, Rive's technology supports the transition to more sustainable energy practices within the petroleum industry.

Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.

[x+1] is the only marketing technology company recognized as a leader in both the Forrester DMP and DSP Wave Reports. [x+1] Origin Platform is a programmatic marketing hub that empowers the world's best brands to engage audiences in progressively relevant conversations across a full spectrum of paid and owned digital channels. [x+1] Origin Data Management Platform (DMP), powered by the Predictive Optimization Engine (POE™) and a wholly-integrated DSP, blends first and third-party data with predictive decisioning to engage audiences across online display, mobile web, apps, email, site, and other digital channels. This is why the world’s best brands including seven of the top financial services advertisers rely on [x+1] for their programmatic marketing. The company is headquartered in New York City with offices in Connecticut, Illinois, Michigan and California. For more information visit www.xplusone.com

Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM ™ materials. The company is dedicated to providing the industry’s highest efficiency solar cells to enable CPV as a cost effective energy solution. Founded in 2007, Solar Junction is headquartered in San Jose, California. Investors include New Enterprise Associates, Draper Fisher Jurvetson and Advanced Technology Ventures.

Cenzic specializes in application security testing for enterprise software, focusing on Software as a Service (SaaS) solutions. The company employs advanced techniques that extend beyond traditional signature-based tools to automatically identify vulnerabilities within applications. Cenzic's offerings include security testing for mobile, web, and cloud applications, as well as comprehensive training programs in security and penetration testing. Additionally, Cenzic provides professional implementation training and consulting services, both on-site and remotely, to enhance software engineering practices and bolster application security for its clients.

Handango provides smartphone applications globally for the [BlackBerry](/organization/blackberry), [Palm](/organization/palm), Windows Mobile, [Symbian OS](http://www.crunchbase.com/organization/symbian-software-ltd), and Linux platforms. Leveraging its 140,000+ apps, network of 23,000+ content partners, and vast distribution network, Handango delivers top-selling mobile applications including games, business and entertainment apps and productivity tools to millions of consumers. Applications can be downloaded via www.handango.com, partner Web sites, SD cards and Handango's proprietary on-device catalog, InHand, the industry's leading content delivery platform that allows consumers to purchase mobile apps directly from their smartphone and download them over the air. Handango's unparalleled content expertise has attracted numerous mobile industry partners including [Microsoft](/organization/microsoft), [Verizon Wireless](/organization/verizon), [T-Mobile](/organization/t-mobile), Alltel, AT&T, 3UK, LG, SoftBank, Sony Ericsson, Samsung, Best Buy, The CarPhone Warehouse, CNET, and AOL.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists' skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio's products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications.

Coskata, Inc. is a biology-based renewable energy company, with technology for the production of liquid fuels. Using proprietary microorganisms and transformative bioreactor designs, the company will produce ethanol from a wide variety of input materials to provide economic, environmental, and national security benefits.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.